In line with these studies, the use of PCSK9 inhibitors was associated with a moderately increased risk of AD in an AD risk patient collective but not associated with the general development of cognitive dysfunction (Giugliano et al., 2017; Williams et al., 2020). Here, PCSK9 is linked to Alzheimer disease.